130 related articles for article (PubMed ID: 33027304)
21. Patient-derived xenografts from non-small cell lung cancer brain metastases are valuable translational platforms for the development of personalized targeted therapy.
Lee HW; Lee JI; Lee SJ; Cho HJ; Song HJ; Jeong DE; Seo YJ; Shin S; Joung JG; Kwon YJ; Choi YL; Park WY; Lee HM; Seol HJ; Shim YM; Joo KM; Nam DH
Clin Cancer Res; 2015 Mar; 21(5):1172-82. PubMed ID: 25549722
[TBL] [Abstract][Full Text] [Related]
22. Generation of stable PDX derived cell lines using conditional reprogramming.
Borodovsky A; McQuiston TJ; Stetson D; Ahmed A; Whitston D; Zhang J; Grondine M; Lawson D; Challberg SS; Zinda M; Pollok BA; Dougherty BA; D'Cruz CM
Mol Cancer; 2017 Dec; 16(1):177. PubMed ID: 29212548
[TBL] [Abstract][Full Text] [Related]
23. Establishment of an orthotopic patient-derived xenograft mouse model using uveal melanoma hepatic metastasis.
Kageyama K; Ohara M; Saito K; Ozaki S; Terai M; Mastrangelo MJ; Fortina P; Aplin AE; Sato T
J Transl Med; 2017 Jun; 15(1):145. PubMed ID: 28645290
[TBL] [Abstract][Full Text] [Related]
24. IL2RG-deficient minipigs generated via CRISPR/Cas9 technology support the growth of human melanoma-derived tumours.
Ren J; Yu D; Fu R; An P; Sun R; Wang Z; Guo R; Li H; Zhang Y; Li Z; Yang YG; Li W; Hai T; Hu Z
Cell Prolif; 2020 Oct; 53(10):e12863. PubMed ID: 32871045
[TBL] [Abstract][Full Text] [Related]
25. CEP-28122, a highly potent and selective orally active inhibitor of anaplastic lymphoma kinase with antitumor activity in experimental models of human cancers.
Cheng M; Quail MR; Gingrich DE; Ott GR; Lu L; Wan W; Albom MS; Angeles TS; Aimone LD; Cristofani F; Machiorlatti R; Abele C; Ator MA; Dorsey BD; Inghirami G; Ruggeri BA
Mol Cancer Ther; 2012 Mar; 11(3):670-9. PubMed ID: 22203728
[TBL] [Abstract][Full Text] [Related]
26. Patient-Derived Tumor Xenografts Are Susceptible to Formation of Human Lymphocytic Tumors.
Bondarenko G; Ugolkov A; Rohan S; Kulesza P; Dubrovskyi O; Gursel D; Mathews J; O'Halloran TV; Wei JJ; Mazar AP
Neoplasia; 2015 Sep; 17(9):735-741. PubMed ID: 26476081
[TBL] [Abstract][Full Text] [Related]
27. Bridging tumor genomics to patient outcomes through an integrated patient-derived xenograft platform.
Gandara DR; Mack PC; Bult C; Li T; Lara PN; Riess JW; Astrow SH; Gandour-Edwards R; Cooke DT; Yoneda KY; Moore EH; Pan CX; Burich RA; David EA; Keck JG; Airhart S; Goodwin N; de Vere White RW; Liu ET
Clin Lung Cancer; 2015 May; 16(3):165-72. PubMed ID: 25838158
[TBL] [Abstract][Full Text] [Related]
28. Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts.
Capasso A; Lang J; Pitts TM; Jordan KR; Lieu CH; Davis SL; Diamond JR; Kopetz S; Barbee J; Peterson J; Freed BM; Yacob BW; Bagby SM; Messersmith WA; Slansky JE; Pelanda R; Eckhardt SG
J Immunother Cancer; 2019 Feb; 7(1):37. PubMed ID: 30736857
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of anti-PD-1-based therapy against triple-negative breast cancer patient-derived xenograft tumors engrafted in humanized mouse models.
Rosato RR; Dávila-González D; Choi DS; Qian W; Chen W; Kozielski AJ; Wong H; Dave B; Chang JC
Breast Cancer Res; 2018 Sep; 20(1):108. PubMed ID: 30185216
[TBL] [Abstract][Full Text] [Related]
30. Establishment of a platform of non-small-cell lung cancer patient-derived xenografts with clinical and genomic annotation.
Kang HN; Choi JW; Shim HS; Kim J; Kim DJ; Lee CY; Hong MH; Park SY; Park AY; Shin EJ; Lee SY; Pyo KH; Yun MR; Choi HM; Lee SS; Kim SY; Lee H; Paik S; Cho BC; Lee JG; Kim HR
Lung Cancer; 2018 Oct; 124():168-178. PubMed ID: 30268457
[TBL] [Abstract][Full Text] [Related]
31. Organoid Cultures as Preclinical Models of Non-Small Cell Lung Cancer.
Shi R; Radulovich N; Ng C; Liu N; Notsuda H; Cabanero M; Martins-Filho SN; Raghavan V; Li Q; Mer AS; Rosen JC; Li M; Wang YH; Tamblyn L; Pham NA; Haibe-Kains B; Liu G; Moghal N; Tsao MS
Clin Cancer Res; 2020 Mar; 26(5):1162-1174. PubMed ID: 31694835
[TBL] [Abstract][Full Text] [Related]
32. Establishing metastatic patient-derived xenograft model for colorectal cancer.
Zhang Y; Lee SH; Wang C; Gao Y; Li J; Xu W
Jpn J Clin Oncol; 2020 Sep; 50(10):1108-1116. PubMed ID: 32579167
[TBL] [Abstract][Full Text] [Related]
33. Establishing an immunocompromised porcine model of human cancer for novel therapy development with pancreatic adenocarcinoma and irreversible electroporation.
Hendricks-Wenger A; Aycock KN; Nagai-Singer MA; Coutermarsh-Ott S; Lorenzo MF; Gannon J; Uh K; Farrell K; Beitel-White N; Brock RM; Simon A; Morrison HA; Tuohy J; Clark-Deener S; Vlaisavljevich E; Davalos RV; Lee K; Allen IC
Sci Rep; 2021 Apr; 11(1):7584. PubMed ID: 33828203
[TBL] [Abstract][Full Text] [Related]
34. The ability to form primary tumor xenografts is predictive of increased risk of disease recurrence in early-stage non-small cell lung cancer.
John T; Kohler D; Pintilie M; Yanagawa N; Pham NA; Li M; Panchal D; Hui F; Meng F; Shepherd FA; Tsao MS
Clin Cancer Res; 2011 Jan; 17(1):134-41. PubMed ID: 21081655
[TBL] [Abstract][Full Text] [Related]
35. Patient-Derived Xenograft Establishment from Human Malignant Pleural Mesothelioma.
Wu L; Allo G; John T; Li M; Tagawa T; Opitz I; Anraku M; Yun Z; Pintilie M; Pitcher B; Liu G; Feld R; Johnston MR; de Perrot M; Tsao MS
Clin Cancer Res; 2017 Feb; 23(4):1060-1067. PubMed ID: 27683181
[No Abstract] [Full Text] [Related]
36. Promising preclinical platform for evaluation of immuno-oncology drugs using Hu-PBL-NSG lung cancer models.
Pyo KH; Kim JH; Lee JM; Kim SE; Cho JS; Lim SM; Cho BC
Lung Cancer; 2019 Jan; 127():112-121. PubMed ID: 30642538
[TBL] [Abstract][Full Text] [Related]
37. High metastatic efficiency of human sarcoma cells in Rag2/gammac double knockout mice provides a powerful test system for antimetastatic targeted therapy.
Nanni P; Nicoletti G; Landuzzi L; Croci S; Murgo A; Palladini A; Antognoli A; Ianzano ML; Stivani V; Grosso V; Maira SM; García-Echeverría C; Scotlandi K; De Giovanni C; Lollini PL
Eur J Cancer; 2010 Feb; 46(3):659-68. PubMed ID: 20031388
[TBL] [Abstract][Full Text] [Related]
38. An improved method to build lung cancer PDX models by surgical resection samples and its association with B7-H3 expression.
Wang Y; Zhang B; Huang H; Wang T
Transl Cancer Res; 2019 Dec; 8(8):2848-2857. PubMed ID: 35117042
[TBL] [Abstract][Full Text] [Related]
39. Personalizing non-small cell lung cancer treatment through patient-derived xenograft models: preclinical and clinical factors for consideration.
Fuchs V; Sobarzo A; Msamra M; Kezerle Y; Linde L; Sevillya G; Anoze A; Refaely Y; Cohen AY; Melamed I; Azriel A; Shoukrun R; Raviv Y; Porgador A; Peled N; Roisman LC
Clin Transl Oncol; 2024 Mar; ():. PubMed ID: 38553659
[TBL] [Abstract][Full Text] [Related]
40. Establishment and Characterization of Histologically and Molecularly Stable Soft-tissue Sarcoma Xenograft Models for Biological Studies and Preclinical Drug Testing.
Cornillie J; Wozniak A; Li H; Wang Y; Boeckx B; Gebreyohannes YK; Wellens J; Vanleeuw U; Hompes D; Stas M; Sinnaeve F; Wafa H; Lambrechts D; Debiec-Rychter M; Sciot R; Schöffski P
Mol Cancer Ther; 2019 Jun; 18(6):1168-1178. PubMed ID: 30962320
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
